QLT PhotoTherapeutics (QLTI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Julian who wrote (751)	11/18/1999 7:41:00 PM
From: Edward W. Richmond	Read Replies (1) of 1321

Julian, I found the analyst recommendations to be fascinating. In particular, Merill Lynch's "Near-term neutral" to be a little humourous. Remember the ML analyst's recommendation to SELL QLT and BUY Xillix Technologies. QLT pre-split is $135.50($C) and Xillix is $0.15($C). ML has long been negative on this stock and it looks like the FDA is not going to change their minds. I'd like to know the recommendations of other companies that have been consistently negative in their ratings in the past. For example in June 1998. Yorkton - underperform First Marathon - underperform Levesque Beaubien - sell Unfortunately, shortly after this date, the names of the brokerages making the recommendations were no longer included in the Investor's Digest. Small wonder! With the name comes accountability. Regards, Ed

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next